Last reviewed · How we verify
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus
Approved treatments
- Caverject · Pfizer
- Prostavasin · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Congenital Heart Defect Requiring Open Patent Ductus Arteriosus patent landscape — cliff calendar, originator estates, attackable patents
- Congenital Heart Defect Requiring Open Patent Ductus Arteriosus treatment landscape brief
- Congenital Heart Defect Requiring Open Patent Ductus Arteriosus treatment updates RSS
Frequently asked questions about Congenital Heart Defect Requiring Open Patent Ductus Arteriosus
What drugs treat Congenital Heart Defect Requiring Open Patent Ductus Arteriosus?
Tracked treatments include Caverject, Prostavasin.
What is the treatment for Congenital Heart Defect Requiring Open Patent Ductus Arteriosus?
Standard treatment for Congenital Heart Defect Requiring Open Patent Ductus Arteriosus includes Caverject, Prostavasin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Congenital Heart Defect Requiring Open Patent Ductus Arteriosus patent cliff · Congenital Heart Defect Requiring Open Patent Ductus Arteriosus CI report
- Treatment: Caverject · Pfizer
- Treatment: Prostavasin · Hannover Medical School
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing